David Brabham, DO
Cardiovascular Disease · Amarillo, TXNPI 1447424007
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $94,125 of the $120,968 with a category attached, or 77.8%. 27 manufacturers reported payments, led by Boehringer Ingelheim at 33.9% of the total. Among cardiovascular disease clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 379 payments — averaging $319.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$41K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$27K
- Lilly USA, LLC$17K
- Pfizer$8K
- Bayer$7K
- Cordis US CORP.$6K
- plus $15K from 21 others
Across 1,303 payments — averaging $8734.14 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$4.9M
- Novartis$3.5M
- CSL Behring$744K
- Eli Lilly$434K
- Janssen Research & Development, LLC$344K
- Boehringer Ingelheim International GmbH$330K
- plus $1.2M from 13 others
What the payments were for
- Consulting fees$13,44011%
- Speaking & faculty fees$94,12578%
- Travel & lodging$4,0393%
- Food & beverage$9,2448%
- Education$1210%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 42 | $40,981 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 24 | $26,537 |
| Lilly USA, LLC | 21 | $16,645 |
| Pfizer | 18 | $8,373 |
| Bayer | 11 | $7,127 |
| Cordis US CORP. | 13 | $6,119 |
| E.r. Squibb & Sons, L.L.C. | 29 | $5,355 |
| Abbott | 107 | $3,523 |
| Cardinal Health 200 LLC | 4 | $2,750 |
| Abiomed | 47 | $1,058 |
| Novartis | 10 | $972 |
| Boston Scientific | 10 | $420 |
| Biotronik Inc. | 9 | $227 |
| Medtronic | 13 | $189 |
| Edwards Lifesciences | 7 | $135 |
| AstraZeneca | 2 | $134 |
| Portola Pharmaceuticals, LLC | 1 | $125 |
| Philips North America LLC | 1 | $84 |
| Astellas Pharma US Inc | 2 | $45 |
| Cook Medical LLC | 1 | $39 |
| Penumbra, Inc. | 1 | $38 |
| Shockwave Medical, Inc | 1 | $24 |
| Acist Medical Systems, Inc. | 1 | $18 |
| Terumo Medical Corporation | 1 | $15 |
| Novo Nordisk | 1 | $15 |
| Regeneron Healthcare Solutions, Inc. | 1 | $13 |
| Merck | 1 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$57,409
- LifeVest$26,497
- ELIQUIS$12,216
- MYNX CONTROL VENOUS$3,600
- Kerendia$3,442
- MynxGrip Vascular Closure Device$2,700
- MYNX CONTROLTM$2,700
- LEQVIO$679
- Ultreon$235
- Impella$228
- ANDEXXA$125
- Supera peripheral stent system$121
- CARDIOMEMS$113
- Watchman$111
- JETi All In One Non-Sterile Kit$105
- Orsiro Mission$104
How this compares
$120,968 in reported general payments places this provider in the 95th percentile of 1,515 cardiovascular disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 802 | $806,992 |
| EntrestoSacubitril/Valsartan | 669 | $644,930 |
| JardianceEmpagliflozin | 490 | $407,715 |
| CamzyosMavacamten | 21 | $167,462 |
| XareltoRivaroxaban | 108 | $115,073 |
| BrilintaTicagrelor | 45 | $35,144 |
| Praluent PenAlirocumab | 36 | $24,046 |
| KerendiaFinerenone | 18 | $21,518 |
| Repatha SureclickEvolocumab | 31 | $20,516 |
| Carvedilol | 1,504 | $11,259 |
| Spironolactone | 1,204 | $10,287 |
| MultaqDronedarone Hcl | 12 | $8,561 |
| VascepaIcosapent Ethyl | 26 | $8,347 |
| Rosuvastatin Calcium | 611 | $7,546 |
| ClopidogrelClopidogrel Bisulfate | 786 | $7,076 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $8,373 | $806,992802 claims |
| NovartisEntresto | $972 | $644,930669 claims |
| Boehringer IngelheimJardiance | $40,981 | $407,715490 claims |
| E.r. Squibb & Sons, L.L.C.Camzyos | $5,355 | $167,46221 claims |
| AstraZenecaBrilinta | $134 | $35,14445 claims |
| BayerKerendia | $7,127 | $21,51818 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,515 cardiovascular disease providers in Texas.
Other cardiovascular disease in Amarillo
- Ramin Farzaneh-FarDallas$17.1M
- John OsborneGrapevine$1.3M
- Darren McGuireDallas$1.2M
- Peter McCulloughDallas$664K
- Ann NavarDallas$616K
- Biykem BozkurtHouston$606K
- Milton PackerDallas$530K
- Amarinder BindraDallas$512K
- Robert SalazarKingwood$478K
- Reynolds DelgadoHouston$471K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.